B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy  

作　　者：Xinyu Tian Xiangyun Zheng Dong Tian 

机构地区：[1]Department of Thoracic Surgery,West China Hospital,Sichuan University,37 Guoxue Alley,Chengdu,610041,China [2]Lung Transplant Research Laboratory,Institute of Thoracic Oncology,West China Hospital,Sichuan University,37 Guoxue Alley,Chengdu,610041,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第11期5149-5150,共2页信号转导与靶向治疗（英文）

基　　金：the Key Research and Development Project of Sichuan Provincial Science and Technology Department(No.23ZDYF2875).

摘　　要：Recently,Lloyd Bod et al.published a study in Nature that identified the B-cell immune checkpoint T cell immunoglobulin and mucin domain 1(TIM-1)and mechanistically elucidated that targeting TIM-1 enhances the responses to type I interferon(IFN-I),promotes B cells antigen presentation and activation,subsequently enhances anti-tumour responses of CD4^(+) and CD8^(+)T cells and inhibits tumour growth.This study provides important implications for anti-tumour therapy.

关 键 词：TUMOUR INTERFERON 

分 类 号：R730.51[医药卫生—肿瘤]